Press release - 11/01/2021 CureVac’s COVID-19 Vaccine Candidate, CVnCoV, Demonstrated Efficient Protection of Non-Human Primates During SARS-CoV-2 Challenge Infection CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today announced the publication of preclinical data demonstrating the induction of robust antibody and T cell responses of its COVID-19 vaccine candidate, CVnCoV, in non-human primates. https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevacs-covid-19-vaccine-candidate-cvncov-demonstrated-efficient-protection-non-human-primates-during-sars-cov-2-challenge-infe
New method for analysing blood samples - 26/11/2020 Personalised therapy monitoring for malignant melanomas Immunotherapy has greatly improved the survival chances of patients with malignant melanoma. A study has now begun at the Department of Dermatology at the University Hospital of Tübingen to develop a way to monitor the course of treatment as effectively as possible. It involves personalised monitoring using liquid biopsies in addition to conventional PET/CT examinations. This analysis procedure of blood samples could enable closer monitoring of…https://www.gesundheitsindustrie-bw.de/en/article/news/personalised-therapy-monitoring-malignant-melanomas
Inside the fight against COVID-19 - 28/10/2020 A new immunotherapeutic agent for treating severe COVID-19 cases Apogenix, a Heidelberg-based biopharmaceutical company specialising in innovative immunotherapeutics, has initiated a Phase II clinical trial with asunercept, the company’s lead drug candidate for treating severe cases of COVID-19. The fusion protein blocks the CD95-ligand-mediated death of epithelial cells in the lung and thus prevents damage to the organ.https://www.gesundheitsindustrie-bw.de/en/article/news/new-immunotherapeutic-agent-treating-severe-covid-19-cases
Biochip systems - 02/09/2020 Miniature organs with great potential Dr. Peter Loskill and his team at the Fraunhofer Institute in Stuttgart and the University Hospital of Tübingen are developing what is known as an "organ-on-a-chip" (OoC). An OoC is a microfluidic system that simulates small functional units of organ tissue. OoCs can be used in different ways: in basic and pharmaceutical research as well as in clinical research and application, where they might render many animal experiments…https://www.gesundheitsindustrie-bw.de/en/article/news/miniature-organs-great-potential
Affimed GmbH - 01/07/2020 "Innate cell engager" fighting against cancer In the fight against tumour cells, d Affimed GmbH from Heidelberg relies entirely on the weapons of the innate immune system. Affimed has developed special innate cell engagers, which are bispecific antibodies that recognise tumour cells and bring them together with natural killer cells and macrophages of the innate immune system, which then kill the tumour cells. Clinical trials using the AFM13 molecule are ongoing.https://www.gesundheitsindustrie-bw.de/en/article/news/innate-cell-engager-fighting-against-cancer
Multiple sclerosis - 12/03/2020 Direct application of biopharmaceuticals through the nose into the brain There is currently no cure for multiple sclerosis, the most common neurological autoimmune disease in humans. Biopharmaceuticals that can delay the course of the disease or diminish its effects are often prevented from being fully effective by the blood-brain barrier. A European consortium led by the Fraunhofer IGB, Stuttgart is developing a new technology that can transport an innovative active ingredient directly to the central nervous system.https://www.gesundheitsindustrie-bw.de/en/article/news/Direct-application-of-biopharmaceuticals-through-the-nose-into-the-brain
Article - 10/07/2019 More than just a nut – new products for the bioeconomy Plants are often used for one particular purpose only. However, walnut trees have much more to offer than just delicious nuts. The AlpBioEco project is studying the potential of walnut trees for the bioeconomy and how the potential can be exploited commercially. The international team of researchers is also focusing on apples and herbs.https://www.biooekonomie-bw.de/en/articles/news/mehr-als-eine-harte-nuss-neue-produkte-fur-die-biookonomie
Article - 11/06/2019 New pathogens in beef and cow's milk contributing to the risk of cancer A team of researchers led by Nobel laureate Prof. Dr. med. Dr. h.c. mult. Harald zur Hausen has discovered a new type of infectious agent in dairy and meat products produced from European cattle that increases the risk for colon and breast cancer. These so-called Bovine Meat and Milk Factors (BMMFs) are small DNA molecules that are similar in sequence to both bacterial plasmids and certain viruses.https://www.gesundheitsindustrie-bw.de/en/article/news/new-pathogens-in-beef-and-cows-milk-contributing-to-the-risk-of-cancer
Expert interview - 13/05/2019 Innovation management in the life sciences – Inova DE provides insights Personalized medicine, medical technology, digital health and artificial intelligence are revolutionizing diagnostics and product development. Analyses are becoming faster and more precise, and data volumes can now be networked and used effectively. The goal of improving people's quality of life is within reach, and this will also strengthen Germany’s future viability. However, not every good idea can be turned into a marketable commodity.…https://www.gesundheitsindustrie-bw.de/en/article/news/innovation-management-in-the-life-sciences-inova-de-provides-insights
Article - 16/04/2019 Tumour monitoring using liquid biopsy Liquid biopsy, the analysis of cancer biomarkers and circulating tumour cells in body fluids such as blood, is revolutionising the diagnosis and monitoring of cancer. It has also been possible to expand circulating tumour cells from the blood under laboratory conditions. It is expected that in the future, liquid biopsy will be able to precisely characterise tumour cells at every stage of a cancer.https://www.gesundheitsindustrie-bw.de/en/article/news/tumour-monitoring-using-liquid-biopsy
Dossier - 15/04/2019 The alternative: “bioplastics” Plastic waste takes years to decompose and pollutes the environment. Nevertheless, plastics are an indispensable part of everyday life. It is therefore all the more important to find a meaningful alternative that is sustainable, environmentally friendly and has better properties and more functionality than conventional plastics. In addition, such an alternative should not be dependent in any way on fossil resources.https://www.biooekonomie-bw.de/en/articles/dossiers/the-alternative-bioplastics
Expert interview on NTDs – part 1 - 11/04/2019 Neglected tropical diseases – Carsten Köhler: impulses from Baden-Württemberg More than one billion people worldwide suffer from neglected tropical diseases (NTDs). NTDs are mostly poverty-related infectious diseases that prevail in tropical countries due to lack of research and measures to detect, prevent and control them. Dr. Dr. Carsten Köhler reports on the political, economic and scientific contributions Germany and Baden-Württemberg can make to successfully change this situation.https://www.gesundheitsindustrie-bw.de/en/article/news/vernachlaessigte-tropenkrankheiten-carsten-koehler-impulse-aus-baden-wuerttemberg
Article - 03/04/2019 HKK Bionics empowers hand gripping functions A spin-off from the Ulm University of Applied Sciences is aiming to provide people whose hands have been paralysed due to accident or illness with a new kind of orthopaedic aid. Dominik Hepp and Tobias Knobloch are currently starting serial production of a hand orthosis prototype. The two medical engineers from Ulm, who founded HKK Bionics GmbH in 2017, plan to commence final tests in 2019.https://www.gesundheitsindustrie-bw.de/en/article/news/hkk-bionics-empowers-hand-gripping-functions
Article - 02/04/2019 Simple sugar could soon compete with glyphosate For many decades, glyphosate has been a common component of agricultural pesticides worldwide, although it is a controversial herbicide that may be harmful. The good news is that a more sustainable alternative is now in sight: researchers from the University of Tübingen have discovered a sugar molecule called 7-deoxy-sedoheptulose (7dSh) which inhibits the growth of plants and microorganisms, but appears to be completely harmless to human cells.https://www.biooekonomie-bw.de/en/articles/news/simple-sugar-could-soon-compete-with-glyphosate
Article - 27/03/2019 Residues from biogas plants as feed for algae Algae are frugal organisms. They require only light, water, minerals and carbon dioxide to be able to produce biomass. These properties will now be exploited economically in a two-year research project. Dr. Stefan Sebök from the University of Hamburg plans to study the holistic utilisation of degradation products of a biogas plant in Wallerstädten by linking them to land-based algae cultivation.https://www.biooekonomie-bw.de/en/articles/news/residues-from-biogas-plants-as-feed-for-algae
Article - 22/03/2019 Personalised therapies for treating metastasing breast cancer Breast cancer is characterised by broad genetic diversity. Successful treatment is made even more difficult by the fact that, in advanced breast cancer, the properties of metastases often differ significantly from the primary tumour. The Heidelberg CATCH study is now collecting genetic profiles from patients' metastasis tissue samples, which can be used to tailor therapy to individual requirements.https://www.gesundheitsindustrie-bw.de/en/article/news/personalisierte-therapieansaetze-bei-metastasiertem-brustkrebs
Article - 21/03/2019 Education as the key to a successful transition into a bioeconomy National and international policy papers emphasize the role of the education sector in the transition into a bioeconomy. On the practical level, various actors are working on programmes to prepare professionals for future challenges. The University of Hohenheim, for example, offers a bioeconomy master's programme and is one of the universities that have laid the cornerstone for the “European Bioeconomy University” consortium. https://www.biooekonomie-bw.de/en/articles/news/bildung-als-schluessel-fuer-eine-erfolgreiche-biooekonomie-transformation
Article - 24/01/2019 Scientists to combat antibiotic-resistant bacteria in wastewater In Germany, around 1,500 tonnes of antibiotics per year are administered to humans and animals. As a result, more and more bacteria are developing resistance to common antibiotics. As part of HyReKA, a cooperative project funded by the BMBF, scientists led by Professor Thomas Schwartz from the KIT are investigating how antibiotic-resistant pathogens spread and how they can be prevented from doing so.https://www.gesundheitsindustrie-bw.de/en/article/news/scientists-to-combat-antibiotic-resistant-bacteria-in-wastewater
Article - 24/01/2019 Scientists to combat antibiotic-resistant bacteria in wastewater In Germany, around 1,500 tonnes of antibiotics per year are administered to humans and animals. As a result, more and more bacteria are developing resistance to common antibiotics. As part of HyReKA, a cooperative project funded by the BMBF, scientists led by Professor Thomas Schwartz from the KIT are investigating how antibiotic-resistant pathogens spread and how they can be prevented from doing so.https://www.biooekonomie-bw.de/en/articles/news/scientists-to-combat-antibiotic-resistant-bacteria-in-wastewater
Dossier - 20/03/2017 Lignin – a natural resource with huge potential Petroleum is the raw material for basic chemicals. Growing demand and dwindling resources mean that the chemical industry is increasingly focusing on renewable resources. Lignin is a wood component that is proving to be a promising resource. It is currently almost exclusively used for generating energy, although it could also be used for other purposes. In Baden-Württemberg, a research consortium is specifically focused on exploring its…https://www.biooekonomie-bw.de/en/articles/dossiers/lignin-a-natural-resource-with-huge-potential
Event - 06/12/2016 Meet & Match "Challenges in early Development and Innovation in Drug Delivery" Karlsruhe, Meet & Match https://www.bio-pro.de/en/events/past-events/meet-match-challenges-in-early-development-and-innovation-in-drug-delivery
Dossier - 14/06/2016 CRISPR/Cas – genome editing is becoming increasingly popular https://www.gesundheitsindustrie-bw.de/en/article/dossier/crisprcas-genome-editing-is-becoming-increasingly-popular
Dossier - 14/06/2016 CRISPR/Cas – genome editing is becoming increasingly popular https://www.biooekonomie-bw.de/en/articles/dossiers/crisprcas-genome-editing-is-becoming-increasingly-popular
Dossier - 09/03/2015 Advances in the study and treatment of liver diseases https://www.gesundheitsindustrie-bw.de/en/article/dossier/advances-in-the-study-and-treatment-of-liver-diseases